Oligodendrocyte dysfunction and subsequent myelin breakdown represent a critical yet underappreciated mechanism in the pathogenesis of neurodegenerative diseases. This pathway page documents how oligodendrocyte precursor cells (OPCs), mature oligodendrocytes, and myelin integrity are compromised in Alzheimer's Disease, Parkinson's Disease, Progressive Supranuclear Palsy (PSP), and Multiple Sclerosis. Understanding these mechanisms reveals potential therapeutic targets and explains white matter abnormalities observed in vivo.
Oligodendrocytes are the myelin-producing cells of the central nervous system (CNS), responsible for ensheathing axons with multilamellar myelin sheaths that enable rapid saltatory conduction. Beyond their well-known role in conduction velocity, oligodendrocytes provide critical metabolic support to axons through the lactate shuttle, maintain axonal ion homeostasis, and support overall neuronal health. The dysfunction or loss of oligodendrocytes therefore has devastating consequences beyond simple demyelination — it initiates a cascade of axonal degeneration, neural network disruption, and progressive cognitive decline.
The white matter abnormalities frequently observed on MRI scans of patients with neurodegenerative diseases are not mere incidental findings but reflect fundamental pathological processes involving oligodendrocyte dysfunction. These include white matter hyperintensities, diffusion tensor imaging abnormalities, and, in advanced cases, overt white matter atrophy. The presence and severity of these white matter changes correlate strongly with clinical outcomes, making oligodendrocyte dysfunction a critical determinant of disease progression.
OPCs (Oligodendrocyte Precursor Cells) are the resident stem cells of the white matter, capable of generating new oligodendrocytes throughout life. In neurodegenerative diseases, OPC function is compromised through multiple mechanisms[1]:
Proliferation Defects
Differentiation Failure
Senescence
Iron Dysregulation
Cellular Energy Dysfunction
The Demyelination process involves[5]:
Myelin breakdown releases:
Iron is abundantly present in myelin (second highest concentration in the brain after ferritin). When myelin breaks down, iron is released into the extracellular space[6]:
Ferrous Iron (Fe²⁺) Accumulation
Ferritin Saturation
Transferrin Saturation
This creates a vicious cycle: iron → oxidative stress → oligodendrocyte damage → more myelin breakdown → more iron release[7].
Myelin loss leads to axonal degeneration through[8]:
Energy Failure
Sodium Channel Dysregulation
Wallerian Degeneration
The relationship between oligodendrocyte dysfunction and neuroinflammation is bidirectional[9]:
Microglial Activation
Inflammatory Cytokine Effects
In AD, oligodendrocyte dysfunction contributes to disease progression through[10]:
White Matter Hyperintensities
Myelin Breakdown Products
Iron Accumulation
OPC Response
Tau Relationship
Parkinson's disease shows prominent oligodendrocyte involvement[13]:
Oligodendrocyte Loss
Iron Overload
Myelin Abnormalities
α-Synuclein Impact
PSP shows particularly prominent oligodendroglial involvement[15]:
4R-Tau in Oligodendrocytes
Globus Pallidus Vulnerability
White Matter Degeneration
MS represents the prototypical demyelinating disease[16]:
Autoimmune Demyelination
OPC Recruitment
Remyelination Failure
Progressive Phase
Remyelination Strategies[17]
Iron Chelation
Neuroprotection
Lactate Transport Enhancement
Iron Homeostasis Modulation
OPC Senolytics
Differentiation Promoters
Current clinical trials targeting oligodendrocyte dysfunction include:
Young K, et al. Oligodendrocyte precursor cell proliferation in the aging brain. Journal of Neuroscience. 2013. ↩︎
Franklin RJ, Ffrench-Constant C. "Remyelination in the CNS". Nature Reviews Neuroscience. 2008. ↩︎
Nicholas SP, et al. "Oligodendrocyte precursor cell senescence in the aging brain". Glia. 2019. ↩︎
Connor JR, Menzies SL. "Iron in oligodendrocytes and myelination". Journal of Neuroscience Research. 1995. ↩︎
Petrosyan OA, et al. "Demyelination and remyelination in AD". Neurobiology of Aging. 2012. ↩︎
Ward RJ, et al. "Iron and oxidative stress in neurodegeneration". Biochemical Society Transactions. 2014. ↩︎
Wang Z, et al. "Iron homeostasis in oligodendrocytes". Cellular and Molecular Neurobiology. 2020. ↩︎
Rinholm JE, et al. "Regulation of axonal energy by oligodendrocytes". Nature Neuroscience. 2011. ↩︎
Butovsky O, et al. "Microglia in CNS neurodegeneration". Nature Neuroscience. 2014. ↩︎
Prins D, Scheltens P. "White matter hyperintensities, cognitive decline, and dementia". Alzheimer's & Dementia. 2015. ↩︎
Ishii T, et al. "Myelin basic protein in AD cerebrospinal fluid". Journal of Alzheimer's Disease. 2019. ↩︎
Raven EP, et al. "Iron accumulation in AD white matter". Acta Neuropathologica. 2018. ↩︎
Barkholt P, et al. "Oligodendrocyte loss in PD". NPJ Parkinson's Disease. 2022. ↩︎
Dexter DT, et al. "Iron in substantia nigra in PD". Journal of Neurochemistry. 1989. ↩︎
Axelsen M, et al. "Myelin abnormalities in PSP". Journal of Neuropathology & Experimental Neurology. 2018. ↩︎
Bergers E, et al. "White matter lesions in MS". Brain. 2020. ↩︎
Sim FJ, et al. "OPC differentiation in demyelinating diseases". Annals of Neurology. 2016. ↩︎
Lee Y, et al. "Lactate shuttle in white matter". Nature Neuroscience. 2012. ↩︎